Pain Therapeutics is a medical research company specializing in the discovery and development of novel proprietary painkillers. We believe our lead drug candidates, OxyTrex(TM) and MorViva(TM), may offer more pain relief (with no increase in side-effects) and lower tolerance/dependence, withdrawal effects or addiction potential compared to conventional forms of oxycodone and morphine. Our clinical results to date show that our drug candidates may provide numerous benefits, including enhanced pain relief with no increase in side effects and prolonged pain relief. Our pre-clinical results also demonstrate a lack of opioid tolerance, physical dependence, withdrawal effects or addiction potential in animals.
People
Margareta Hammarlund-Udenaes (Board Member)
Elliot Krane (Board Member)
Mary Kreek (Board Member)
Frank Porreca (Board Member)
Robert Gussin (Board Member)
News
Durect holds follow-on private sale to raise $10M
September 14, 2009 5:03 pm
Pharmaceutical company Durect has struck a deal with Venrock to sell 4.4 million shares of common stock at $2.25 each… Continue reading ⟩
Pain treatment maker TorreyPines saved by Raptor merger
July 30, 2009 6:52 pm
TorreyPines Therapeutics, maker of pain management medication, has skirted failure through a $1.4 million merger deal with Raptor Therapeutics. The… Continue reading ⟩
Life-science briefing: Monday, March 24, 2008
March 24, 2008 8:17 pm
TODAY’S HEADLINES: Trius Therapeutics raises $30M for new antibiotics (release) Genomas gets $1.2M grant for genomic side-effect tests (release) Provasculon… Continue reading ⟩